Neurocrine Biosciences (NBIX) EBT (2010 - 2026)

Neurocrine Biosciences (NBIX) has reported EBT for 17 consecutive years, with $162.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBT rose 1.69% year-over-year to $162.2 million; the trailing twelve-month figure through Jun 2026 stood at $940.2 million (up 78.37% YoY), and the FY2025 full-year result was $705.4 million, up 45.14% from the prior year.
• EBT fell to $162.2 million in Q2 2026 per NBIX's latest filing, from $246.8 million in the prior quarter.
• Across five years, EBT topped out at $291.8 million in Q3 2025 and bottomed at -$103.3 million in Q1 2023.
• Historically, EBT has averaged $119.2 million across 5 years, with a median of $119.8 million in 2022.
• The sharpest annual moves came in 2023 and 2026: EBT slumped 582.71% in 2023, then jumped 1578.91% in 2026.
• Over 5 years, EBT stood at $117.9 million in 2022, then jumped by 68.11% to $198.2 million in 2023, then decreased by 17.96% to $162.6 million in 2024, then soared by 47.23% to $239.4 million in 2025, then plunged by 32.25% to $162.2 million in 2026.
• According to Business Quant data, EBT over the past three periods registered $162.2 million, $246.8 million, and $239.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.